Vivodyne grows human tissues at scale to replace animal drug testing — and is already working with top-10 pharma

Vivodyne

Andrei Georgescu's pitch starts with a failure rate: 19 out of 20 drugs that work in animals fail in humans. Vivodyne's answer is to remove animals from the equation and test directly on human tissue grown at industrial scale.

The company grows centimeter-scale human tissue samples, each containing hundreds of thousands of cells, with visible self-assembling blood vessels. It produces tens to hundreds of thousands of these tissues at a time, enough to test 50,000 drug permutations from a single patient biopsy. The cells come from donated blood or tumor biopsies, and Georgescu is explicit that these are primary human cells, not stem cell lines or transformed cell lines, which matters for fidelity.

“VivaDyne grows human tissues at very massive scale — we can test drugs in humans without testing in people, many times the total amount of clinical trials run in the US every year. Nineteen out of twenty drugs fail because animal experiments don't translate to people. We can cure cancer in mice and then they fail in people.”

Why now

The enabling unlock was throughput. Growing functional tissue requires finding an extremely narrow set of conditions, what Georgescu describes as getting a ball to sit in a small valley at the top of a mountain. Hitting that target across thousands of variables only became tractable with modern robotics and the ability to run large numbers of formulation experiments in parallel.

Where it sits in the drug development pipeline

Vivodyne is working with the large majority of top-10 pharma companies, and Georgescu says most of those projects involve drugs that fail to translate even from primates to humans. That positions the technology not as a pre-mouse screening tool but as a replacement for the entire animal testing cascade, from discovery through clinical trial support. The logic is that when drugs are working in mice, dogs, and monkeys but still failing in humans 95% of the time, the animal data is not predictive enough to justify the cost.

The search space problem compounds this. Single-target drug strategies are hitting diminishing returns against diseases like cancer, Alzheimer's, and fibrosis. Testing combinatorial, multi-target approaches across that space requires a volume of experiments that animal models cannot economically support.

Regulatory tailwind

The FDA has passed three modernization acts pushing adoption of animal alternatives, which Georgescu describes as a strong tailwind rather than a regulatory obstacle. The pressure is sharpest for biologics, including antibody-based therapies and bispecific antibody drug conjugates, which are designed to bind human-specific targets and are therefore particularly hard to test in non-human animals.

Personalized medicine

Georgescu confirms the company is already doing patient-specific testing. Because the tissues must originate from someone's cells, the model naturally extends to oncology cases where a patient's tumor biopsy can be scaled into tens of thousands of tissue samples, each exposed to different drug combinations, before any treatment decision is made.

The company is based in San Francisco. Georgescu co-founded it with his PhD advisor Dan, who had invented the underlying organ-chip concept, and Georgescu brought the high-throughput microfluidics background needed to scale it.